Undervalued Small Caps With Insider Action In Hong Kong October 2024

In This Article:

In recent weeks, the Hong Kong market has experienced a surge in optimism, with the Hang Seng Index climbing significantly as investors respond to Beijing's comprehensive support measures. This positive sentiment comes amid global economic fluctuations and geopolitical tensions that have impacted markets worldwide, highlighting the potential opportunities within small-cap stocks that may be overlooked by broader market movements. Identifying promising small-cap stocks often involves looking for those with strong fundamentals and insider activity, which can indicate confidence in their future prospects despite current volatility.

Top 10 Undervalued Small Caps With Insider Buying In Hong Kong

Name

PE

PS

Discount to Fair Value

Value Rating

Beijing Chunlizhengda Medical Instruments

14.6x

3.2x

47.40%

★★★★★☆

Edianyun

NA

0.6x

42.71%

★★★★★☆

Vesync

7.6x

1.1x

-8.78%

★★★★☆☆

Ferretti

10.8x

0.7x

47.43%

★★★★☆☆

Gemdale Properties and Investment

NA

0.2x

41.54%

★★★★☆☆

China Lesso Group Holdings

6.5x

0.4x

-574.92%

★★★☆☆☆

Skyworth Group

6.0x

0.1x

-320.41%

★★★☆☆☆

Lee & Man Paper Manufacturing

7.8x

0.5x

-59.78%

★★★☆☆☆

Guangdong Kanghua Healthcare Group

13.7x

0.3x

5.68%

★★★☆☆☆

Emperor International Holdings

NA

0.9x

22.92%

★★★☆☆☆

Click here to see the full list of 10 stocks from our Undervalued SEHK Small Caps With Insider Buying screener.

Let's dive into some prime choices out of from the screener.

Beijing Chunlizhengda Medical Instruments

Simply Wall St Value Rating: ★★★★★☆

Overview: Beijing Chunlizhengda Medical Instruments is engaged in the manufacture and trading of surgical implants, instruments, and related products with a market cap of CN¥4.08 billion.

Operations: The company's revenue primarily stems from the manufacture and trading of surgical implants, instruments, and related products, totaling CN¥1.05 billion. The gross profit margin showed a trend of fluctuation over recent periods, reaching 70.00% in the latest quarter ending October 8, 2024. Operating expenses are significant with sales and marketing being a major component at CN¥327.73 million for the same period.

PE: 14.6x

Beijing Chunlizhengda Medical Instruments, a Hong Kong-listed company, is experiencing insider confidence with share purchases throughout 2024. Despite a sales decline to CNY 380 million and net income dropping to CNY 79 million for the first half of the year compared to last year, earnings are projected to grow annually by 19.33%. The firm proposed an interim dividend of RMB 0.83 per ten shares, reflecting potential future value despite its reliance on external borrowing for funding.